Intuitive Surgical (NASDAQ:ISRG) PT Raised to $500.00 at Mizuho

Intuitive Surgical (NASDAQ:ISRG) had its price target upped by Mizuho from $440.00 to $500.00 in a research report issued to clients and investors on Thursday. Mizuho’s price target points to a potential upside of 5.36% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on ISRG. Raymond James boosted their price objective on Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday. Stifel Nicolaus raised their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Royal Bank of Canada increased their price objective on Intuitive Surgical from $515.00 to $525.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Truist Financial upped their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research note on Monday. Finally, Morgan Stanley increased their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $484.15.

Intuitive Surgical Stock Down 0.4 %

NASDAQ:ISRG traded down $2.04 on Thursday, reaching $474.55. 651,718 shares of the company’s stock traded hands, compared to its average volume of 1,459,238. The stock has a 50-day simple moving average of $482.49 and a 200-day simple moving average of $436.65. The firm has a market cap of $168.32 billion, a PE ratio of 85.71, a P/E/G ratio of 5.40 and a beta of 1.39. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the previous year, the business posted $1.18 earnings per share. Intuitive Surgical’s quarterly revenue was up 14.5% on a year-over-year basis. On average, equities analysts anticipate that Intuitive Surgical will post 5.22 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $446.60, for a total value of $167,921.60. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,458,979.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Myriam Curet sold 2,818 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $446.60, for a total value of $167,921.60. Following the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,458,979.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock valued at $25,528,753 in the last quarter. Company insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Creekmur Asset Management LLC grew its holdings in shares of Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares during the period. Ridgewood Investments LLC bought a new position in Intuitive Surgical during the second quarter worth about $26,000. Delos Wealth Advisors LLC raised its position in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares during the period. LRI Investments LLC acquired a new position in shares of Intuitive Surgical in the first quarter valued at about $30,000. Finally, LGT Financial Advisors LLC lifted its position in Intuitive Surgical by 415.4% during the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 54 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.